ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Nanobubble-based anti-hepatocellular carcinoma therapy combining immune check inhibitors and sonodynamic therapy

Liu, Yun; Yang, ShiQi; Zhou, Qing; Zhou, Jun; Li, Jinlin; Ma, Yao; Hu, Bing; Liu, Chaoqi*; Zhao, Yun*武汉大学; 1; y
Nanoscale Advances2022-11-8DOI: 10.1039/d2na00322h
2被引6阅读
引用收藏
分享

摘要

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, posing a global threat to human healthcare, and current approved treatment strategies do not produce satisfactory outcomes. Here, nanobubbles (NBs) were prepared that carried Immune Check Inhibitors (ICIs), PD-L1 antibody (PD-L1 Ab) and sonodynamic agent CHLORIN E6 (Ce-6); the anti-cancer properties of these NBs were analyzed from the point of view of immune and sonodynamic therapies. The PD-L1 Ab/Ce-6-NBs could inhibit tumor growth through regulating reactive oxygen species (ROS) production, apoptosis, and most importantly, the function of associated immunocytes, including natural killer cells and lymphocytes. The tumor tissues highly expressed markers of immunogenic tumor cell death (ICD) in which the expression of calreticulin (CRT) and ICD-related immune cytokines (CD80, CD86, INF-gamma, and IL-2) were increased in PD-L1 Ab/Ce-6-NB treated mice. PD-L1 Ab/Ce-6-NBs also promoted murine spleen lymphocyte proliferation and cytotoxic activity, as well as CD8+ T cell infiltration in the tumor tissues, and downregulation of the PD-L1 protein and mRNA expression. Furthermore, Bax expression was increased and Bcl-2 was inhibited at the mRNA and protein levels in a murine subcutaneous transplanted tumor model. These results indicate that PD-L1 Ab/Ce-6-NBs can induce ROS-dependent ICD to further boost anti-cancer immune responses under the action of targeting the PD-1/PD-L1 immune check point in the tumor microenvironment as a promising therapeutic agent for HCC.

学科与关键词

关键词
DELIVERYCHEMOTHERAPYBLOCKADEPD-1
相关
加载中…
  • Nanobubble-mediated co-delivery of Ce6 and miR-195 for synergized sonodynamic and checkpoint blockade combination therapy with elicitation of robust immune response in hepatocellular carcinoma
    Ma, Yao; Li, Jinlin; Zhao, Yun; Hu, Bing; Liu, Yun*; Liu, Chaoqi*European Journal of Pharmaceutics and Biopharmaceutics, 2022, 181: 36-48.被引 4
  • Nanobubbles containing PD-L1 Ab and miR-424 mediated PD-L1 blockade, and its expression inhibition to enable and potentiate hepatocellular carcinoma immunotherapy in mice
    Liu, Yun; Xie, Qian; Ma, Yao; Lin, Chen; Li, Jinlin; Hu, Bing; Liu, Chaoqi*; Zhao, Yun*International Journal of Pharmaceutics, 2022, 629: 122352.被引 3
  • Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma
    Chen, Yezi; Luo, Xiaoqin; Liu, Yun; Zou, Yunlei; Yang, Shiqi; Liu, Chaoqi*; Zhao, Yun*International Journal of Nanomedicine, 2022, 17: 3989-4008.被引 7
查看全部 →

发表信息

论文状态
公开发表
期刊
Nanoscale Advances
发表日期
2022-11-08
卷期
第 4 卷, 第 22 期
页码
4847-4862
DOI
10.1039/d2na00322h
期刊等级
3区
成果收录
SCIE
资助标注
Medical College of Three Gorges University; Hubei Key Laboratory of the Tumor Microenvironment and Immunotherapy Foundation [2018KZL02, 2019KZL10]; National Natural Science Foundation of China [81673675]

作者

  • L

    Liu, Yun (第一作者)

    china three gorges univ · 1 · wuhan univ

  • Y

    Yang, ShiQi

    china three gorges univ

查看全部 9 位作者收起作者
  • Z

    Zhou, Qing

    wuhan univ

  • Z

    Zhou, Jun

    1 · china three gorges univ

  • L

    Li, Jinlin

    china three gorges univ

  • M

    Ma, Yao

    1 · china three gorges univ

  • H

    Hu, Bing

    china three gorges univ

  • L

    Liu, Chaoqi (通讯)

    china three gorges univ

  • Z

    Zhao, Yun (通讯)

    china three gorges univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417